Goldman Sachs
MREO

Goldman Sachs’s Mereo BioPharma MREO Stock Holding History

Goldman Sachs’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,026
Closed -$11.7K – 6808
2025
Q4 		$11.7K Sell
28,026
-2,335,998
-99% -$4.45M ﹤0.01% 6360
2025
Q3 		$4.87M Sell
2,364,024
-726,044
-23% -$1.34M ﹤0.01% 3671
2025
Q2 		$8.37M Buy
3,090,068
+964,148
+45% +$2.33M ﹤0.01% 2922
2025
Q1 		$4.78M Buy
2,125,920
+6,068
+0.3% +$17.2K ﹤0.01% 3400
2024
Q4 		$7.42M Buy
2,119,852
+111,471
+6% +$438K ﹤0.01% 3066
2024
Q3 		$8.25M Sell
2,008,381
-499,132
-20% -$2.06M ﹤0.01% 2910
2024
Q2 		$9.03M Buy
2,507,513
+263,699
+12% +$854K ﹤0.01% 2591
2024
Q1 		$7.4M Buy
2,243,814
+220,142
+11% +$745K ﹤0.01% 2756
2023
Q4 		$4.67M Hold
2,023,672
– – ﹤0.01% 3215
2023
Q3 		$2.61M Buy
2,023,672
+41,266
+2% +$54.8K ﹤0.01% 3551
2023
Q2 		$2.62M Sell
1,982,406
-280,379
-12% -$325K ﹤0.01% 3665
2023
Q1 		$1.6M Sell
2,262,785
-31,981
-1% -$28.8K ﹤0.01% 4034
2022
Q4 		$1.72M Buy
2,294,766
+1,585,640
+224% +$1.3M ﹤0.01% 4051
2022
Q3 		$611K Sell
709,126
-8,329
-1% -$10.2K ﹤0.01% 4843
2022
Q2 		$804K Buy
717,455
+2,270
+0.3% +$1.76K ﹤0.01% 4774
2022
Q1 		$801K Buy
715,185
+2,822
+0.4% +$3.65K ﹤0.01% 5000
2021
Q4 		$1.14M Buy
+712,363
New +$1.42M ﹤0.01% 4733

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Goldman Sachs's MREO Position: Q1 2026 in Review

Goldman Sachs sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 28,026 shares — an estimated $11.7K sold.

Goldman Sachs first reported a position in MREO in Q4 2021 and held it in 17 quarters. The position peaked at $9.03M in Q2 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Goldman Sachs reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 28,026 Mereo BioPharma shares in Q1 2026, an estimated $11.7K.
  • Goldman Sachs first reported a position in Mereo BioPharma in Q4 2021 and held it in 17 quarters.
  • Goldman Sachs's Mereo BioPharma position peaked at $9.03M in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.